By JESSICA DaMASSA, WTF HEALTH

Hinge Health kicked off 2021 with a massive $300M Series D, driving the digital health musculoskeletal care company to a $3B valuation that, normally, would have sent health tech pundits into full-on IPO rumor mode…except that Hinge Health’s co-founder & CEO Daniel Perez beat them to it! We get into the details behind those comments (from what shall now be known as “the chatty Reuters interview”) where he not only revealed the company’s IPO plans, but also talked about how Hinge is well on it’s way to hit $200M in revenue. If 2021 is a year that Dan says will be focused on getting the business “operationally mature” enough to go public, what, exactly will be on the agenda? We dive into the competitive landscape, talk market size (Dan says more than 50% of employees on employer sponsored plans already have access to Hinge Health), and explore whether or not there are designs to expand into comorbidities common to back and joint pain, like mental health, obesity, diabetes, etc. Says Dan, “We’re going to use the capital to really invest in our innovation and R&D team and to stay different. We’re not just going to do the obvious moves.” Tune in for all the details on exactly what that means and why Dan thinks it’s central to Hinge Health’s market leadership in the MSK care space.